Vapotherm Reports First Quarter 2023 Financial Results

03 May 2023
www.biospace.com
Financial Statement
EXETER, N.H.--(BUSINESS WIRE)-- Vapotherm Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP operating expenses for the first quarter of 2023 were $19.8 million and Non-GAAP cash operating expenses were $16.4 million. Both decreased as a result of the Company’s Path to Profitability initiatives: GAAP operating expenses decreased by $3.0 million over the fourth quarter of 2022 Non-GAAP cash operating expenses decreased by $1.6 million over the fourth quarter of 2022 The Company’s unrestricted cash balance was $25.7 million at the end of the first quarter of 2023 The Company closed a $23 million private placement in February 2023 Net cash burn of $11.0 million in the first quarter was $2.0 million less than net cash burn in the fourth quarter of 2022 “We had solid execution in the first quarter and are pleased with the positive trends we’re seeing in key elements of our business,” said Joseph Army, President and CEO. “Market receptivity to HVT 2.0 continues to be strong and, as expected, HVT 2.0 capital sales increased over the fourth quarter of 2022 despite a challenging capital equipment environment. We also continued to make progress on our Path to Profitability initiatives which resulted in sequential quarter improvements in gross margin, operating expenses and cash burn.” Results for the Three Months March 31, 2023 The following table reflects the Company’s net revenue for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 Change (in thousands, except percentages) Amount % of Revenue Amount % of Revenue $ % Revenue Capital (product & lease revenue) $ 3,901 22.0 % $ 4,050 18.7 % $ (149 ) (3.7 )% Disposables 12,417 70.0 % 14,879 68.8 % (2,462 ) (16.5 )% Service and other 1,413 8.0 % 2,693 12.5 % (1,280 ) (47.5 )% Total net revenue $ 17,731 100.0 % $ 21,622 100.0 % $ (3,891 ) (18.0 )% Net revenue for the first quarter of 2023 was $17.7 million. Disposables and capital revenue were lower in the first quarter of 2023 as compared to the first quarter of 2022 since the prior period included significant Omicron related customer demand, especially for disposables. There was little to no COVID related customer demand in the first quarter of 2023. Revenue information by geography is summarized as follows: Three Months Ended March 31, 2023 2022 Change (in thousands, except percentages) Amount % of Revenue Amount % of Revenue $ % United States $ 13,014 73.4 % $ 16,499 76.3 % $ (3,485 ) (21.1 )% International 4,717 26.6 % 5,123 23.7 % (406 ) (7.9 )% Total net revenue $ 17,731 100.0 % $ 21,622 100.0 % $ (3,891 ) (18.0 )% Gross profit and gross margin for the first quarter of 2023 was $6.2 million and 35.0%, respectively. In the first quarter of 2023, gross margin increased by 750 basis points over gross margin of 27.5% in the fourth quarter of 2022. Total operating expenses were $19.8 million in the first quarter of 2023, a decrease of $8.0 million as compared to the same period last year. Non-GAAP cash operating expenses, excluding impairment charges, loss on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, termination benefits, gain (loss) from deconsolidation, and change in fair value of contingent consideration were $16.4 million in the first quarter of 2023 compared to $24.3 million in the first quarter of 2022 and $18.0 million in the fourth quarter of 2022. The decreases in operating expenses and Non-GAAP cash operating expenses were primarily due to the Company’s path-to-profitability initiatives. Operating expenses in the first quarter of 2023 include a non-cash impairment charge of $0.4 million related to the write-down of operating lease right-of-use assets to their estimated fair value. Net loss for the first quarter of 2023 was $18.1 million, or $0.45 per share, compared to $22.9 million, or $0.87 per share, in the first quarter of 2022. Net loss per share was based on 40,608,605 and 26,321,087 weighted average shares outstanding for the first quarter of 2023 and 2022, respectively. Adjusted EBITDA was negative $9.2 million for the first quarter of 2023 as compared to negative $15.3 million for the first quarter of 2022. The improvement in Adjusted EBITDA was primarily due to the Company’s path-to-profitability initiatives. Cash Position Cash and cash equivalents were $25.7 million as of March 31, 2023 compared to $15.7 million as of December 31, 2022. The increase in cash in the first quarter of 2023 was due to net proceeds received under the Company’s February 2023 private placement financing, partially offset by its net loss. The Company expects that cash burn the first quarter of the year will represent more than half of the total cash burn in 2023. Fiscal 2023 Outlook The Company continues to expect full year revenue to be between $77 million and $79 million, full year gross margins of 48% to 50% and full year operating expenses of $76 million to $78 million. Fiscal 2023, non-GAAP cash operating expenses excluding additional items as detailed below are still expected to be in the range of $60 million to $62 million. While the Company expects disposable revenue to account for 75% of our total revenue over the long-term, the Company anticipates that the contribution of disposable revenue as a percentage of total revenue may be slightly lower than this in 2023 given the market receptivity to HVT 2.0. Conference Call Information Management will host a conference call at 4:30 p.m. Eastern Time on May 3, 2023 to discuss the results of the quarter with a question and answer session. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: . The webcast replay will be available on the Vapotherm website for 12 months following completion of the call. A replay of this conference call will be available by telephone through May 10, 2023 by dialing +1 (800) 770-2030 in the U.S. or +1 (647) 362-9199 outside of the U.S. The replay access code is 6585549. Website Information Vapotherm routinely posts important information for investors on the Investor Relations section of its website, . Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document. Non-GAAP Financial Measures This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, non-GAAP operating expenses excluding impairment of long-lived and intangible assets and loss on disposal of property and equipment, and non-GAAP cash operating expenses excluding additional items, including stock-based compensation expense, depreciation and amortization, termination benefits, gain (loss) from deconsolidation, and change in fair value of contingent consideration, which differ from operating expenses calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). EBITDA represents net loss less interest expense, net, income tax provision or benefit, and depreciation and amortization, and Adjusted EBITDA represents EBITDA as further adjusted for the impact of foreign currency loss or gain, change in fair value of contingent consideration, stock-based compensation expense, impairment of long lived and intangible assets, gain (loss) from deconsolidation, and loss on debt extinguishment. Since these adjustments to the GAAP measures are highly variable, difficult to predict and of a size that could have substantial impact on Vapotherm’s reported results of operations for a period, Vapotherm cannot provide without unreasonable effort a quantitative reconciliation to the most directly comparable GAAP measures for its 2023 financial guidance regarding non-GAAP cash operating expenses. The Company has reconciled all historical non-GAAP financial measures with the most directly comparable GAAP financial measures in tables accompanying this release. These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures, as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period. These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in the Adjusted EBITDA presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company’s definitions of Adjusted EBITDA and non-GAAP operating expenses excluding impairment of long-lived and intangible assets and loss on disposal of property and equipment and non-GAAP cash operating expenses excluding the additional items detailed below, are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. About Vapotherm Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.9 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit . Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems’ mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication. Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company’s expected net revenue, including revenue breakdown, gross margin, operating expenses and non-GAAP cash operating expenses for fiscal year 2023. In some cases, you can identify forward-looking statements by terms such as “expect,” “continue,” “plan,” “intend,” “will,” “outlook,” “guidance,” or “typically,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future or achieve its 2023 financial guidance including reduced cash burn; risks associated with the move of its manufacturing operations to Mexico; Vapotherm’s ability to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations; Vapotherm’s ability to comply with its financial covenants, execute on its path-to-profitability initiative, convert excess inventory into cash and fund its business through 2023; Vapotherm’s dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability for Precision Flow systems to gain increased market acceptance; Vapotherm’s inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm’s susceptibility to seasonal fluctuations; Vapotherm’s failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of COVID on its business, including its supply chain, and the other risks and uncertainties included under the heading “Risk Factors” in Vapotherm’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 23, 2023, and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Vapotherm’s views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Financial Statements: VAPOTHERM, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) March 31, 2023 December 31, 2022 (unaudited) Assets Current assets Cash and cash equivalents $ 25,713 $ 15,738 Accounts receivable, net of expected credit losses of $251 and $227, respectively 8,403 9,102 Inventories, net 28,499 32,980 Prepaid expenses and other current assets 3,444 2,081 Total current assets 66,059 59,901 Property and equipment, net 25,673 26,636 Operating lease right-of-use assets 5,030 5,805 Restricted cash 1,109 1,109 Goodwill 549 536 Deferred income tax assets 125 96 Other long-term assets 2,102 2,112 Total assets $ 100,647 $ 96,195 Liabilities and Stockholders’ Deficit Current liabilities Accounts payable $ 2,974 $ 2,739 Contract liabilities 1,197 1,216 Accrued expenses and other current liabilities 11,810 15,609 Total current liabilities 15,981 19,564 Long-term loans payable, net 99,270 96,994 Other long-term liabilities 7,750 7,827 Total liabilities 123,001 124,385 Commitments and contingencies Stockholders’ deficit Preferred stock ($0.001 par value) 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022 - - Common stock ($0.001 par value) 175,000,000 shares authorized as of March 31, 2023 and December 31, 2022, 46,215,938 and 28,516,047 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 46 29 Additional paid-in capital 485,714 461,940 Accumulated other comprehensive loss (22 ) (157 ) Accumulated deficit (508,092 ) (490,002 ) Total stockholders’ deficit (22,354 ) (28,190 ) Total liabilities and stockholders’ deficit $ 100,647 $ 96,195 VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) Three Months Ended March 31, 2023 2022 (unaudited) Net revenue $ 17,731 $ 21,622 Cost of revenue 11,519 13,730 Gross profit 6,212 7,892 Operating expenses Research and development 3,987 5,549 Sales and marketing 9,592 13,322 General and administrative 5,770 8,954 Impairment of right-of-use assets 432 - Loss on disposal of property and equipment 55 - Total operating expenses 19,836 27,825 Loss from operations (13,624 ) (19,933 ) Other (expense) income Interest expense (4,331 ) (1,747 ) Interest income 28 17 Foreign currency loss (154 ) (69 ) Loss on extinguishment of debt - (1,114 ) Net loss before income taxes $ (18,081 ) $ (22,846 ) Provision for income taxes 9 92 Net loss $ (18,090 ) $ (22,938 ) Other comprehensive loss: Foreign currency translation adjustments 135 (55 ) Total other comprehensive loss 135 (55 ) Total comprehensive loss $ (17,955 ) $ (22,993 ) Net loss per share basic and diluted $ (0.45 ) $ (0.87 ) Weighted-average number of shares used in calculating net loss per share, basic and diluted 40,608,605 26,321,087 VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) Three Months Ended March 31, 2023 2022 Cash flows from operating activities Net loss $ (18,090 ) $ (22,938 ) Adjustments to reconcile net loss to net cash used in operating activities Stock-based compensation expense 2,820 3,446 Depreciation and amortization 1,248 1,391 Provision for credit losses 49 177 Provision for inventory valuation 165 150 Non-cash lease expense 387 519 Change in fair value of contingent consideration - (188 ) Impairment of right-of-use assets 432 - Loss on disposal of property and equipment 55 - Placed units reserve 344 151 Interest paid in-kind 2,194 - Amortization of discount on debt 184 139 Deferred income taxes 9 83 Loss on extinguishment of debt - 1,114 Changes in operating assets and liabilities: Accounts receivable 663 805 Inventories 4,384 (1,650 ) Prepaid expenses and other assets (1,234 ) (927 ) Accounts payable 114 84 Contract liabilities (25 ) (652 ) Accrued expenses and other current liabilities (3,148 ) (11,882 ) Operating lease liabilities, current and long-term (585 ) (293 ) Net cash used in operating activities (10,034 ) (30,471 ) Cash flows from investing activities Purchases of property and equipment (1,004 ) (3,008 ) Net cash used in investing activities (1,004 ) (3,008 ) Cash flows from financing activities Proceeds from issuance of common stock and pre-funded warrants and accompanying warrants in private placement, net of issuance costs 20,943 - Proceeds from loans, net of discount - 99,094 Repayment of loans - (40,000 ) Payments of debt extinguishment costs - (817 ) Payment of debt issuance costs - (1,365 ) Repayments on revolving loan facility - (6,608 ) Payment of contingent consideration - (135 ) Proceeds from exercise of stock options - 12 Net cash provided by financing activities 20,943 50,181 Effect of exchange rate changes on cash, cash equivalents and restricted cash 70 (10 ) Net increase in cash, cash equivalents and restricted cash 9,975 16,692 Cash, cash equivalents and restricted cash Beginning of period 16,847 57,324 End of period $ 26,822 $ 74,016 Supplemental disclosures of cash flow information Interest paid during the period $ 1,284 $ 983 Property and equipment purchases in accounts payable and accrued expenses $ 354 $ 1,581 Debt issuance costs in accounts payable and accrued expenses $ - $ 202 Issuance of common stock to satisfy contingent consideration $ - $ 5,630 Issuance of common stock warrants in conjunction with long term debt $ 28 $ 1,157 Issuance of common stock upon vesting of restricted stock units $ - $ 10 Non-GAAP Financial Measures The following tables contain a reconciliation of net loss to Adjusted EBITDA for the three months ended March 31, 2023 and 2022, respectively. (unaudited) Three Months Ended March 31, 2023 2022 (in thousands) Net loss $ (18,090 ) $ (22,938 ) Interest expense, net 4,303 1,730 Provision for income taxes 9 92 Depreciation and amortization 1,248 1,391 EBITDA $ (12,530 ) $ (19,725 ) Stock-based compensation 2,820 3,446 Impairment of right-of-use assets 432 - Foreign currency 154 69 Gain from deconsolidation (114 ) - Loss on disposal of property and equipment 55 - Loss on extinguishment of debt - 1,114 Change in fair value of contingent consideration - (188 ) Adjusted EBITDA $ (9,183 ) $ (15,284 ) The following tables contain a reconciliation of operating expenses to non-GAAP operating expenses and non-GAAP cash operating expenses for the three months ended March 31, 2023, December 31, 2022 and March 31, 2022, respectively. (unaudited) Three Months Ended March 31, 2023 December 31, 2022 March 31, 2022 (in thousands) GAAP operating expenses $ 19,836 $ 22,827 $ 27,825 Impairment of long-lived assets (432 ) (1,501 ) - Loss on disposal of property and equipment (55 ) (247 ) - Non-GAAP operating expenses 19,349 21,079 27,825 Stock-based compensation (2,773 ) (2,663 ) (3,218 ) Termination benefits - (30 ) - Depreciation and amortization (305 ) (342 ) (472 ) Gain (loss) from deconsolidation 114 (35 ) - Change in fair value of contingent consideration - - 188 Non-GAAP cash operating expenses $ 16,385 $ 18,009 $ 24,323 Supplemental Operating Metrics March 31, 2023 2022 Change Amount Amount Amount % HVT 2.0 and precision flow units installed base United States 24,488 23,693 795 3.4 % International 12,586 12,038 548 4.6 % Total 37,074 35,731 1,343 3.8 % Three Months Ended March 31, 2023 2022 Change Amount Amount Amount % HVT 2.0 and precision flow units sold and leased United States 260 322 (62 ) (19.3 )% International 127 185 (58 ) (31.4 )% Total 387 507 (120 ) (23.7 )% Disposable patient circuits sold United States 81,219 99,591 (18,372 ) (18.4 )% International 39,184 48,036 (8,852 ) (18.4 )% Total 120,403 147,627 (27,224 ) (18.4 )%
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.